Skip to content
Screener

Innoviva, Inc. INVA Total Equity

Total Equity at other companies

Pfizer logo
PfizerPFE
$90.1B-0.3%
Merck & Co. logo
Merck & Co.MRK
$41.93B-14.4%
AbbVie logo
AbbVieABBV
-$6.66B-569%
Insmed logo
InsmedINSM
$757.49M-39.4%
Savara logo
SavaraSVRA
$176.04M+19.1%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$323.98M+60.0%

Other financials

Income statement

See full
Revenue$119.6M+19.3%
Gross profit$90.6M+9.0%
Operating income$50.9M+4.3%
Net income-$83.4M-231%
EPS (diluted)-$1.14-248%

Balance sheet

See full
Cash & equivalents$570.4M+43.5%
Total debt$269.7M-40.2%
Total assets$1.7B+27.7%

Cash flow

See full
Operating cash flow$52.0M+17.9%
CapEx$429.0K
Free cash flow$51.5M+16.9%

Valuation

See full
Market cap$1.53B+33.1%
Enterprise value$1.22B+2.1%
P/E4.3×-25.4×
P/S3.5×+0.4×

Profitability

See full
Gross margin72.2%-10.9pp
Operating margin36.9%-10.7pp
Net margin81.2%+70.8pp
FCF margin43.1%-11.1pp

Returns & leverage

See full
Return on equity29.1%
Debt / equity0.2×
Current ratio16×+13.4×

Where this comes from

Reported directly by Innoviva, Inc. in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The source filing: Innoviva, Inc.’s 10-Q, filed August 5, 2026. Open the filing →

Filed
Aug 5, 2026, 4:26 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335235

FAQ

What is Innoviva, Inc.'s total equity?
Innoviva, Inc. (INVA) reported total equity of $1.23B in Q2 2026.
What is the long-term trend for Innoviva, Inc.'s total equity?
Over 4 years (2020 to 2025), Innoviva, Inc.'s total equity has grown at a 21.4% compound annual growth rate (CAGR), from $539.91M to $1.17B.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Ask your AI about Innoviva, Inc.'s total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude